Skip to main content
SpringerLink
Log in

Head and Neck Tumors: Viewpoint—Fractionated Radiation Therapy and Chemotherapy

  • Chapter
Principles and Practice of Stereotactic Radiosurgery

  • 2549 Accesses

Abstract

Head and neck cancers are common malignancies that present considerable treatment challenges in terms of disease control and patient morbidity. Over several decades, the management of head and neck malignancies has moved from single modality to multimodality treatment, with an emphasis on disease control and organ preservation. The combination of chemotherapy and radiotherapy forms the cornerstone of current treatment paradigms for locally advanced head and neck cancers. Advances in altered fractionation and delivery techniques, effective chemotherapy combinations, novel biologic treatments, and risk stratification have led to improved disease control, decreased treatment-related morbidity, and improved patient quality of life. The role of stereotactic radiotherapy in head and neck cancers has made considerable advances in the past decade. These advances stem from progress in tumor identification and delineation, image guidance, patient immobilization, and treatment planning and delivery. Stereotactic radiosurgery and stereotactic body radiotherapy are becoming more widely used in the setting of reirradiation for head and neck malignancies. Ongoing research aims to improve the safety and efficacy of stereotactic radiotherapy for head and neck cancers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–52.

    Article  CAS  PubMed  Google Scholar 

  3. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–44.

    Article  PubMed  Google Scholar 

  4. Adelstein DJ, Li Y, Adams GL, Wagner Jr H, Kish JA, Ensley JF, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–8.

    Article  PubMed  Google Scholar 

  5. Calais G, Le Floch O. Concomitant radiotherapy and chemotherapy in the treatment of cancers of the upper respiratory and digestive tracts. Bull Cancer Radiother. 1996;83(4):321–9.

    Article  CAS  PubMed  Google Scholar 

  6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349(22): 2091–8.

    Article  CAS  PubMed  Google Scholar 

  7. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–78.

    Article  CAS  PubMed  Google Scholar 

  8. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Brizel DM, Albers ME, Fisher SR, Scher RL, Richtsmeier WJ, Hars V, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338(25):1798–804.

    Article  CAS  PubMed  Google Scholar 

  10. Al-Sarraf M, Pajak TF, Marcial VA, Mowry P, Cooper JS, Stetz J, et al. Concurrent radiotherapy and chemotherapy with cisplatin in inoperable squamous cell carcinoma of the head and neck. An RTOG study. Cancer. 1987;59(2):259–65.

    Article  CAS  PubMed  Google Scholar 

  11. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet. 2000;355(9208):949–55.

    Article  CAS  PubMed  Google Scholar 

  12. Pignon JP, le Maitre A, Maillard E, Bourhis J. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.

    Article  PubMed  Google Scholar 

  13. Stell PM. Adjuvant chemotherapy in head and neck cancer. Semin Radiat Oncol. 1992;2(3):195–205.

    Article  PubMed  Google Scholar 

  14. Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995; 71(1):83–91.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Bourhis J, Pignon JP. Meta-analyses in head and neck squamous cell carcinoma. What is the role of chemotherapy? Hematol Oncol Clin North Am. 1999;13(4):769,75, vii.

    Google Scholar 

  16. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324(24):1685–90.

    Google Scholar 

  17. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC head and neck cancer cooperative group. J Natl Cancer Inst. 1996;88(13):890–9.

    Article  CAS  PubMed  Google Scholar 

  18. Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91–11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7): 845–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Denis F, Garaud P, Bardet E, Alfonsi M, Sire C, Germain T, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69–76.

    Article  PubMed  Google Scholar 

  20. Lee N, Xia P, Fischbein NJ, Akazawa P, Akazawa C, Quivey JM. Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. Int J Radiat Oncol Biol Phys. 2003;57(1):49–60.

    Article  PubMed  Google Scholar 

  21. Lee N, Puri DR, Blanco AI, Chao KS. Intensity-modulated radiation therapy in head and neck cancers: An update. Head Neck. 2007;29(4):387–400.

    Article  PubMed  Google Scholar 

  22. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys. 2006;64(1):57–62.

    Article  PubMed  Google Scholar 

  23. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64(1):47–56.

    Article  CAS  PubMed  Google Scholar 

  24. Huncharek M, Kupelnick B. Combined chemoradiation versus radiation therapy alone in locally advanced nasopharyngeal carcinoma: Results of a meta-analysis of 1,528 patients from six randomized trials. Am J Clin Oncol. 2002;25(3):219–23.

    Article  PubMed  Google Scholar 

  25. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: A meta-analysis of the published literature. J Clin Oncol. 2004;22(22):4604–12.

    Article  CAS  PubMed  Google Scholar 

  26. Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: RTOG phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Fountzilas G, Ciuleanu E, Bobos M, Kalogera-Fountzila A, Eleftheraki AG, Karayannopoulou G, et al. Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic cooperative oncology group (HeCOG) with biomarker evaluation. Ann Oncol. 2012;23(2):427–35.

    Article  CAS  PubMed  Google Scholar 

  28. Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–9.

    Article  CAS  PubMed  Google Scholar 

  29. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 2007;357(17): 1695–704.

    Article  CAS  PubMed  Google Scholar 

  30. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007;357(17): 1705–15.

    Article  CAS  PubMed  Google Scholar 

  31. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Tortochaux J, et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst. 2009;101(7):498–506.

    Article  CAS  PubMed  Google Scholar 

  32. Cohen E, Karrison T, Kocherginsky M, Chao H, Agulnik M, Mittal B, et al. Docetaxel based chemoradiotherapy plus or minus induction chemotherapy to decrease events in head and neck cancer (DeCIDE). J Clin Oncol. 2012;30(suppl; abstract 5500.

    Google Scholar 

  33. Haddad R, Rabinowits G, Tishler R, Adkins D, Khuri F, Clark J, et al. The PARADIGM study: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). J Clin Oncol. 2012;30 (suppl; abstract 5501).

    Google Scholar 

  34. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58(3):959–65.

    Article  CAS  PubMed  Google Scholar 

  35. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–8.

    Article  CAS  PubMed  Google Scholar 

  36. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–27.

    Article  CAS  PubMed  Google Scholar 

  37. Ang K, Zhang Q, Rosenthal D, Nguyen-Tan P, Sherman E, Weber R, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol 2011;29(suppl; abstract 5500).

    Google Scholar 

  38. Lee NY, Zhang Q, Pfister DG, Kim J, Garden AS, Mechalakos J, et al. Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): A phase 2 multi-institutional trial. Lancet Oncol. 2012;13(2): 172–80.

    Article  CAS  PubMed  Google Scholar 

  39. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, Madeleine MM, et al. Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst. 1998;90(21):1626–36.

    Article  CAS  PubMed  Google Scholar 

  40. Gillison ML, Koch WM, Shah KV. Human papillomavirus in head and neck squamous cell carcinoma: Are some head and neck cancers a sexually transmitted disease? Curr Opin Oncol. 1999; 11(3):191–9.

    Article  CAS  PubMed  Google Scholar 

  41. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709–20.

    Article  CAS  PubMed  Google Scholar 

  42. D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944–56.

    Article  PubMed  Google Scholar 

  43. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, Pinto H, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261–9.

    Article  CAS  PubMed  Google Scholar 

  44. Lewis Jr JS. p16 immunohistochemistry as a standalone test for risk stratification in oropharyngeal squamous cell carcinoma. Head Neck Pathol. 2012;6 Suppl 1:S75–82.

    Article  PubMed  Google Scholar 

  45. Eisbruch A, Marsh LH, Martel MK, Ship JA, Ten Haken R, Pu AT, et al. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing. Int J Radiat Oncol Biol Phys. 1998; 41(3):559–68.

    Article  CAS  PubMed  Google Scholar 

  46. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer. 2000;90(2):92–103.

    Article  CAS  PubMed  Google Scholar 

  47. Puri DR, Chou W, Lee N. Intensity-modulated radiation therapy in head and neck cancers: Dosimetric advantages and update of clinical results. Am J Clin Oncol. 2005;28(4):415–23.

    Article  PubMed  Google Scholar 

  48. Eisbruch A, Harris J, Garden AS, Chao CK, Straube W, Harari PM, et al. Multi-institutional trial of accelerated hypofractionated intensity-modulated radiation therapy for early-stage oropharyngeal cancer (RTOG 00–22). Int J Radiat Oncol Biol Phys. 2010; 76(5):1333–8.

    Article  PubMed Central  PubMed  Google Scholar 

  49. Kam MK, Leung SF, Zee B, Chau RM, Suen JJ, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.

    Article  PubMed  Google Scholar 

  50. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol. 2011; 12(2):127–36.

    Article  PubMed Central  PubMed  Google Scholar 

  51. Mendenhall WM, Riggs CE, Amdur RJ, Hinerman RW, Villaret DB. Altered fractionation and/or adjuvant chemotherapy in definitive irradiation of squamous cell carcinoma of the head and neck. Laryngoscope. 2003;113(3):546–51.

    Article  PubMed  Google Scholar 

  52. Mendenhall WM, Million RR, Stringer SP, Cassisi NJ. Squamous cell carcinoma of the glottic larynx: A review emphasizing the university of Florida philosophy. South Med J. 1999;92(4):385–93.

    Article  CAS  PubMed  Google Scholar 

  53. Wang CC, Efird J, Nakfoor B, Martins P. Local control of T3 carcinomas after accelerated fractionation: A look at the “gap”. Int J Radiat Oncol Biol Phys. 1996;35(3):439–41.

    Article  CAS  PubMed  Google Scholar 

  54. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003; 362(9388):933–40.

    Article  PubMed  Google Scholar 

  55. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, et al. A radiation therapy oncology group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.

    Article  CAS  PubMed  Google Scholar 

  56. Horiot JC, Le Fur R, N’Guyen T, Chenal C, Schraub S, Alfonsi S, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiother Oncol. 1992; 25(4):231–41.

    Article  CAS  PubMed  Google Scholar 

  57. Beitler J, Zhang Q, Fu K, Trotti A, Spencer S, Jones C, et al. RTOG 90-03: Final report. Int J Radiat Oncol Biol Phys. 2012;84(3S):S6.

    Article  Google Scholar 

  58. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368(9538):843.54.

    Article  PubMed  Google Scholar 

  59. Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18(7):1458–64.

    CAS  PubMed  Google Scholar 

  60. Bourhis J, Sire C, Graff P, Gregoire V, Maingon P, Calais G, et al. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99–02): An open-label phase 3 randomised trial. Lancet Oncol. 2012;13(2):145–53.

    Article  PubMed  Google Scholar 

  61. Langer CJ, Harris J, Horwitz EM, Nicolaou N, Kies M, Curran W, et al. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: Results of radiation therapy oncology group protocol 9911. J Clin Oncol. 2007;25(30):4800–5.

    Article  CAS  PubMed  Google Scholar 

  62. Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern cooperative oncology group study E1393. J Clin Oncol. 2001; 19(4):1088–95.

    CAS  PubMed  Google Scholar 

  63. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, et al. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): An intergroup trial of the eastern cooperative oncology group. J Clin Oncol. 2005;23(15):3562–7.

    Article  CAS  PubMed  Google Scholar 

  64. Spencer SA, Wheeler RH, Peters GE, Beenken SW, Meredith RF, Smith J, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol. 1999;22(1):1–5.

    Article  CAS  PubMed  Google Scholar 

  65. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. RTOG 96–10: Reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck. Int J Radiat Oncol Biol Phys. 2001;51(5):1299–304.

    Article  CAS  PubMed  Google Scholar 

  66. Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, et al. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck. Head Neck. 2008;30(3):281–8.

    Article  PubMed  Google Scholar 

  67. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun RJ, et al. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. J Clin Oncol. 2008;26(34):5518–23.

    Article  CAS  PubMed  Google Scholar 

  68. De Crevoisier R, Bourhis J, Domenge C, Wibault P, Koscielny S, Lusinchi A, et al. Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol. 1998;16(11):3556–62.

    PubMed  Google Scholar 

  69. Salama JK, Vokes EE, Chmura SJ, Milano MT, Kao J, Stenson KM, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2006;64(2):382–91.

    Article  PubMed  Google Scholar 

  70. Machtay M, Rosenthal DI, Chalian AA, Lustig R, Hershock D, Miller L, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2004;59(1):72–7.

    Article  CAS  PubMed  Google Scholar 

  71. Tanvetyanon T, Padhya T, McCaffrey J, Zhu W, Boulware D, Deconti R, et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer. J Clin Oncol. 2009;27(12): 1983–91.

    Article  PubMed  Google Scholar 

  72. Langendijk JA, Kasperts N, Leemans CR, Doornaert P, Slotman BJ. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol. 2006;78(3):306–12.

    Article  PubMed  Google Scholar 

  73. Cmelak AJ, Cox RS, Adler JR, Fee Jr WE, Goffinet DR. Radiosurgery for skull base malignancies and nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1997;37(5):997–1003.

    Article  CAS  PubMed  Google Scholar 

  74. Kondziolka D, Lunsford LD. Stereotactic radiosurgery for squamous cell carcinoma of the nasopharynx. Laryngoscope. 1991; 101(5):519–22.

    Article  CAS  PubMed  Google Scholar 

  75. Unger KR, Lominska CE, Deeken JF, Davidson BJ, Newkirk KA, Gagnon GJ, et al. Fractionated stereotactic radiosurgery for reirradiation of head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2010;77(5):1411–9.

    Article  PubMed  Google Scholar 

  76. Cengiz M, Ozyigit G, Yazici G, Dogan A, Yildiz F, Zorlu F, et al. Salvage reirradiation with stereotactic body radiotherapy for locally recurrent head-and-neck tumors. Int J Radiat Oncol Biol Phys. 2011;81(1):104–9.

    Article  PubMed  Google Scholar 

  77. Wang K, Heron DE, Clump DA, Flickinger JC, Kubicek GJ, Rwigema JC, et al. Target delineation in stereotactic body radiation therapy for recurrent head and neck cancer: A retrospective analysis of the impact of margins and automated PET-CT segmentation. Radiother Oncol. 2013;106(1):90–5.

    Article  PubMed  Google Scholar 

  78. Foote RL, Pollock BE, Gorman DA, Schomberg PJ, Stafford SL, Link MJ, et al. Glomus jugulare tumor: Tumor control and complications after stereotactic radiosurgery. Head Neck. 2002;24(4):332,8. discussion 338–9.

    Google Scholar 

  79. Elshaikh MA, Mahmoud-Ahmed AS, Kinney SE, Wood BG, Lee JH, Barnett GH, et al. Recurrent head-and-neck chemodectomas: a comparison of surgical and radiotherapeutic results. Int J Radiat Oncol Biol Phys. 2002;52(4):953–6.

    Article  PubMed  Google Scholar 

  80. Ahn YC, Lee KC, Kim DY, Huh SJ, Yeo IH, Lim DH, et al. Fractionated stereotactic radiation therapy for extracranial head and neck tumors. Int J Radiat Oncol Biol Phys. 2000;48(2):501–5.

    Article  CAS  PubMed  Google Scholar 

  81. Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1099–111.

    Article  CAS  PubMed  Google Scholar 

  82. Buatti JM, Friedman WA, Bova FJ, Mendenhall WM. Linac radiosurgery for locally recurrent nasopharyngeal carcinoma: Rationale and technique. Head Neck. 1995;17(1):14–9.

    Article  CAS  PubMed  Google Scholar 

  83. Ryu S, Khan M, Yin FF, Concus A, Ajlouni M, Benninger MS, et al. Image-guided radiosurgery of head and neck cancers. Otolaryngol Head Neck Surg. 2004;130(6):690–7.

    Article  PubMed  Google Scholar 

  84. Siddiqui F, Patel M, Khan M, McLean S, Dragovic J, Jin JY, et al. Stereotactic body radiation therapy for primary, recurrent, and metastatic tumors in the head-and-neck region. Int J Radiat Oncol Biol Phys. 2009;74(4):1047–53.

    Article  PubMed  Google Scholar 

  85. Roh KW, Jang JS, Kim MS, Sun DI, Kim BS, Jung SL, et al. Fractionated stereotactic radiotherapy as reirradiation for locally recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1348–55.

    Article  PubMed  Google Scholar 

  86. Heron DE, Ferris RL, Karamouzis M, Andrade RS, Deeb EL, Burton S, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: Results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;75(5): 1493–500.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Maryland, 22 South Greene Street, Baltimore, MD, 21201, USA

    Michael Rutenberg & Mohan Suntharalingam

Authors
  1. Michael Rutenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mohan Suntharalingam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohan Suntharalingam .

Editor information

Editors and Affiliations

  1. Department of Neurosurgery, SUNY Upstate Medical University, Syracuse, USA

    Lawrence S. Chin

  2. Dept. of Radiation Oncology, Univ. of Maryland School of Medicine, Baltimore, Maryland, USA

    William F. Regine

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rutenberg, M., Suntharalingam, M. (2015). Head and Neck Tumors: Viewpoint—Fractionated Radiation Therapy and Chemotherapy. In: Chin, L., Regine, W. (eds) Principles and Practice of Stereotactic Radiosurgery. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8363-2_43

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8363-2_43

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8362-5

  • Online ISBN: 978-1-4614-8363-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation